Marc-André Joly
Boehringer Ingelheim
5 Papers
48 Citations
Marc-André Joly is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Pharmacokinetics & Chirality (chemistry). The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Molecular Dynamics Simulations and Structure-Based Rational Design Lead to Allosteric HCV NS5B Polymerase Thumb Pocket 2 Inhibitor with Picomolar Cellular Replicon Potency
Oliver Hucke,René Coulombe,Pierre R. Bonneau,Megan Bertrand-Laperle,Christian Brochu,James Gillard,Marc-André Joly,Serge Landry,Olivier Lepage,Montse Llinas-Brunet,Marc Pesant,Martin Poirier,Maude Poirier,Ginette McKercher,Martin Marquis,George Kukolj,Pierre L. Beaulieu,Timothy A. Stammers +17 more
TL;DR: This approach predicted a small but critical ligand-binding induced movement of a protein backbone region which increases the pocket size and improves access to the backbone carbonyl groups of Val 494 and Pro 495, and was subsequently confirmed by X-ray crystallography.
29
Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype.
Pierre L. Beaulieu,René Coulombe,Jianmin Duan,Gulrez Fazal,Cédrickx Godbout,Oliver Hucke,Araz Jakalian,Marc-André Joly,Olivier Lepage,Montse Llinas-Brunet,Julie Naud,Martin Poirier,Nathalie Rioux,Bounkham Thavonekham,George Kukolj,Timothy A. Stammers +15 more
TL;DR: The structure-based design of a novel lead chemotype that binds to thumb pocket 2 of HCV NS5B polymerase and inhibits cell-based gt1 subgenomic reporter replicons at sub-micromolar concentrations is described.
23
Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus.
Lee Fader,Martine Brault,Jessica Desjardins,Nathalie Dansereau,Louie Lamorte,Sonia Tremblay,François Bilodeau,Josée Bordeleau,Martin Duplessis,Vida Gorys,James Gillard,James L. Gleason,Clint James,Marc-André Joly,Cyrille Kuhn,Montse Llinas-Brunet,Laibin Luo,Louis Morency,Sébastien Morin,Mathieu Parisien,Maude Poirier,Carl Thibeault,Thao Trinh,Claudio Sturino,Sanjay Srivastava,Christiane Yoakim,Michael Franti +26 more
TL;DR: A high-throughput screen based on a viral replication assay was used to identify inhibitors of the human cytomegalovirus and hit compound 1 was identified as a 4 μM inhibitor of HCMV that was specific and selective over other herpes viruses.
Patent
1,8-naphthyridin-2(1h)-one derivatives as cytomegalovirus inhibitors
Lee Fader,Pierre L. Beaulieu,Murray D. Bailey,François Bilodeau,Rebekah J. Carson,André Giroux,Cédrickx Godbout,Oliver Hucke,Marc-André Joly,Mélissa Leblanc,Olivier Lepage,Benoît Moreau,Julie Naud,Martin Poirier,Elisia Villemure +14 more
- 03 Apr 2013
TL;DR: In this article, the Compounds of Formula (I) were defined for the treatment of cytomegalovirus disease and/or infection, wherein n, A, R1, R2, R3 and R5 were used.
Enantiomeric Atropisomers Inhibit HCV Polymerase and/or HIV Matrix: Characterizing Hindered Bond Rotations and Target Selectivity.
Steven R. LaPlante,Pat Forgione,Colette Boucher,René Coulombe,James Gillard,Oliver Hucke,Araz Jakalian,Marc-André Joly,George Kukolj,Christopher T. Lemke,Robert S. McCollum,Steve Titolo,Pierre L. Beaulieu,Timothy A. Stammers +13 more
TL;DR: It was found by X-ray crystallography that one enantiomer of a compound bound to the intended HCV NS5B polymerase target whereas the mirror image atropisomer was able to bind to an unrelated HIV matrix target.